Literature DB >> 15958582

The antitumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction.

Mary M McHugh1, Loretta S Gawron, Sei-Ichi Matsui, Terry A Beerman.   

Abstract

This study examined the extent of chromosome instability induced in cultured human colon carcinoma HCT116 cells by the antitumor radiomimetic enediyne antibiotic C-1027. Spectral karyotype analysis showed frequent intrachromosomal fusions and fragmentations 26 hours after addition of as little as 0.035 nmol/L C-1027. When the concentration was increased to 0.14 nmol/L C-1027, 92% of cells showed chromosomal aberrations compared with only 2.9% after treatment with an equivalent growth inhibitory dose of ionizing radiation (20 Gy). Thus, chromosome misrejoining was associated to a much greater extent with C-1027-induced than with ionizing radiation-induced cell growth inhibition. Despite these aberrations, a large fraction of C-1027-treated cells progressed into G1. Comet analysis showed that these extensive chromosomal anomalies were not due to increased induction or reduced repair of C-1027-induced compared with ionizing radiation-induced strand breaks. Fluorescence in situ hybridization analysis showed that misrejoining of telomere repeats (i.e., chromosomes joined end to end at their telomeres or fused together after complete loss of telomere sequences) was observed within 26 hours of C-1027 addition. The extreme cytotoxicity of C-1027 may reflect both induction and erroneous repair of DNA double-strand break in the whole genome and/or in subgenomic targets such as telomere sequences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958582     DOI: 10.1158/0008-5472.CAN-05-0015

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  The radiomimetic enediyne C-1027 induces unusual DNA damage responses to double-strand breaks.

Authors:  Daniel R Kennedy; Terry A Beerman
Journal:  Biochemistry       Date:  2006-03-21       Impact factor: 3.162

2.  Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.

Authors:  Xing-Qi Li; Zhi-Gang Ouyang; Sheng-Hua Zhang; Hong Liu; Yue Shang; Yi Li; Yong-Su Zhen
Journal:  J Neurooncol       Date:  2014-05-20       Impact factor: 4.130

3.  Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.

Authors:  Qing Zhang; Xiujun Liu; Shuangshuang Xu; Caihong Li; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  Cancer Biother Radiopharm       Date:  2012-05-31       Impact factor: 3.099

4.  Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.

Authors:  Yong-Zhan Zhen; Ya-Jun Lin; Yi Li; Yong-Su Zhen
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

5.  Apoptotic Melanoma B16-F1 Cells Induced by Lidamycin Could Initiate the Antitumor Immune Response in BABL/c Mice.

Authors:  Jian-lin Yang; Ye Qin; Liang Li; Chu-yu Cao; Qing Wang; Qian Li; Ya-feng Lv; Yanlin Wang
Journal:  Oncol Res       Date:  2016-01-21       Impact factor: 5.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.